EndoGastric Solutions Revenue
Medical Equipment Manufacturing • 
Redmond, Washington, United States • 11-20 Employees
EndoGastric Solutions revenue & valuation
| Annual revenue | $26,000,000 |
| Revenue per employee | $1,369,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $83,200,000 |
| Total funding | $18,000,000 |
Key Contacts at EndoGastric Solutions
Chris Bayne
Director, Manufacturing Engineering & Production Operations
Manny Montoya
Director Of Program Sales
John Griffin
Director
Bill Peters
Director Of Sales
Company overview
| Headquarters | 18109 NE 76th St Suite 100, Redmond, WA 98052, US |
| Phone number | +14253079200 |
| Website | |
| NAICS | 3391 |
| SIC | 384 |
| Keywords | General Surgery And Gastroenterology |
| Founded | 2003 |
| Employees | 11-20 |
| Socials |
EndoGastric Solutions Email Formats
EndoGastric Solutions uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@endogastricsolutions.com), used 69.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@endogastricsolutions.com | 69.2% |
{first name}{last name} | johndoe@endogastricsolutions.com | 30.8% |
About EndoGastric Solutions
About EndoGastric Solutions: Based in Redmond, WA, EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company focused on developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of gastroesophageal reflux disease (GERD). EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) procedure—a barely invasive solution that addresses a significant unmet clinical need. About Transoral Incisionless Fundoplication (TIF®) procedure for reflux: Performed without the need for external incisions through the skin, the TIF procedure offers patients who require an anatomical repair another treatment option to correct the underlying cause of GERD. Studies show that for up to three years after the TIF procedure esophageal inflammation (esophagitis) is eliminated and most patients are able to stop using daily PPI medications to control symptoms. For current job opportunities please visit http://www.endogastricsolutions.com/careers To locate a physician visit GERDHelp.com. About EsophyX® technology: The original EsophyX device was cleared by the FDA in 2007. EGS launched the third generation EsophyX device, the EsophyX Z in 2015. The technology has continued to evolve and is a clinically-backed tool for physician use in the treatment of GERD. The EsophyX technology now enables surgeons and gastroenterologists to use a wider selection of endoscopes–including low profile and larger high-definition models—to treat the underlying anatomical cause of GERD. The EsophyX technology is used to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids from washing back up into the esophagus. The device is inserted through the patient’s mouth with direct visual guidance from an endoscope.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
EndoGastric Solutions has 18 employees across 5 departments.
Departments
Number of employees
EndoGastric Solutions Tech Stack
Discover the technologies and tools that power EndoGastric Solutions's digital infrastructure, from frameworks to analytics platforms.
Performance
WordPress plugins
JavaScript libraries
JavaScript libraries
Programming languages
Blogs
Page builders
Widgets
Analytics
Advertising
WordPress plugins
Analytics
United Arab Emirates
Australia
Norway
Frequently asked questions
4.8
40,000 users
